

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
| Drug common name | MAVELERTINIB |
| INN | mavelertinib |
| Description | Mavelertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target epidermal growth factor receptor. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F |
| PDB | — |
| CAS-ID | 1776112-90-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989970 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | YXX2180047 (ChemIDplus, GSRS) |
